Press Releases

Press Releases
Date Title and Summary View
Jun 6, 2017 40.3% Overall Response Rate (ORR) with Median Duration of Response of 5.8 Months and 19.3% Complete Response (CR) Rate with Median Duration of Response of 8.8 Months in Patients With a CR Overall Safety Profile was Consistent with Previously Reported Data Simultaneous Online Public...
Jun 5, 2017 - 100% of the 15 evaluable patients in active dose cohorts (doses above 50 x 106) achieved an objective response; overall response rate (ORR) across all cohorts (n=18) is 89% - - 73% of evaluable patients in active dose cohorts achieved a very good partial response (VGPR) or better; 27% complete r...
Jun 1, 2017 - Companies expect to report top-line results from the Phase 3 studies in mid-2018 - SUMMIT, N.J. & CAMBRIDGE, Ma.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ: CELG) and Acceleron Pharma Inc. (NASDAQ: XLRN) today announced that they have completed target enrollment in the MEDALIS...
May 22, 2017 Study met the primary endpoint of annualized relapse rate (ARR) and key secondary MRI endpoints of T2 and GdE lesions, compared to interferon (IFN) β-1a (Avonex®); a very low rate of disability progression observed across the three treatment groups in the pooled analysis; disability endpoint not met ...
May 17, 2017 Presentations will include multiple solid tumor and blood cancers while highlighting the value of innovative research SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ: CELG) today announced that data from a broad range of company-sponsored and investigator-initiated studies ...
May 6, 2017 - Preliminary results show that treatment with investigational drug luspatercept achieves meaningful erythroid response rates and transfusion independence in first-line, lower-risk myelodysplastic syndromes patients - - Celgene and Acceleron plan to initiate a Phase 3 trial in first-line,...
May 3, 2017 SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) plans to present at three upcoming investor conferences where Celgene management will provide an overview of the Company. The conferences will be webcast live and will be available in the Investor Relations section of the Company's website at www.c...
Apr 27, 2017 - Net Product Sales of $2.95B in Q1:17; Increased 18% Y/Y - REVLIMID® Net Product Sales of $1.9B in Q1:17; Increased 20% Y/Y - Raising 2017 EPS Guidance - Positive phase II STEPSTONE data with ozanimod in Crohn's disease; Phase III trial initiation pla...
Apr 3, 2017 SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) has received a Paragraph IV Notice Letter advising that Teva Pharmaceuticals USA, Inc. submitted an Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug Administration (FDA) seeking authorization from the FDA to manufacture an...
Apr 3, 2017 SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) will host a conference call and live audio webcast on Thursday, April 27, 2017 at 9 a.m. ET to discuss first quarter 2017 financial and operational results. The webcast can be accessed from the Investor Relations page at www.celgene.com. ...
FirstPrevious
4
... NextLast
Add to Briefcase = add release to Briefcase